| Literature DB >> 32471384 |
Illya Martynov1,2, Jessica Klima-Frysch3, Joachim Schoenberger3.
Abstract
BACKGROUND: Thousands of research articles on neuroblastoma have been published over the past few decades; however, the heterogeneity and variable quality of scholarly data may challenge scientists or clinicians to survey all of the available information. Hence, holistic measurement and analyzation of neuroblastoma-related literature with the help of sophisticated mathematical tools could provide deep insights into global research performance and the collaborative architectonical structure within the neuroblastoma scientific community. In this scientometric study, we aim to determine the extent of the scientific output related to neuroblastoma research between 1980 and 2018.Entities:
Keywords: Children; Network analysis; Neuroblastoma; Research performance; Scientometrics
Mesh:
Year: 2020 PMID: 32471384 PMCID: PMC7260742 DOI: 10.1186/s12885-020-06974-3
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Overall publication performance in neuroblastoma research from 1980 to 2018, presented as a total number of publications per year, the corresponding annual growth rate, the average citations they received, and the associated h-index
Fig. 2Detailed profile of citation rate and dynamics on neuroblastoma during the last 38 years
Top 10 contributing authors in field of neuroblastoma research
| Rank | Author | Number of publications | H index | G Index | M Index | Articles Fractionalized | Average citation per item | Sum of time cited ( without self citation) | PY start |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Berthold F | 169 | 45 | 80 | 1.3 | 27.6 | 43.4 | 7420 (6838) | 1986 |
| 2 | Matthay KK | 165 | 63 | 113 | 2.2 | 21.4 | 81.0 | 13,373 (12,305) | 1992 |
| 3 | Cheung NKV | 160 | 50 | 76 | 1.4 | 33.4 | 42.53 | 6975 (61645) | 1986 |
| 4 | Maris JM | 158 | 56 | 110 | 2.2 | 19.0 | 79.8 | 12,661 (11,878) | 1995 |
| 5 | Cohn SL | 156 | 54 | 96 | 1.6 | 20.4 | 64.2 | 10,016 (9434) | 1987 |
| 6 | Nakagawara A | 118 | 33 | 67 | 0.9 | 17.8 | 40.9 | 4954 (4685) | 1986 |
| 7 | Seeger RC | 116 | 57 | 108 | 1.6 | – | 100.2 | 11,725 (11,368) | 1986 |
| 8 | Speleman F | 116 | 39 | 72 | 1.5 | – | 48.4 | 5614 (5132) | 1994 |
| 9 | Tonini GP | 116 | 27 | 54 | 0.8 | 18.4 | 29.3 | 3429 (3163) | 1987 |
| 10 | Hero B | 112 | 39 | 68 | 1.5 | – | 44.7 | 5014 (4673) | 1995 |
Affiliation of the highly cited authors
Berthold F: University of Cologne, Department of Pediatric Oncology and Hematology, University of Cologne, Koeln, Germany
Matthay KK: Department of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA
Cheung NKV: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
Maris JM: The Children’s Hospital of Philadelphia, Division of Oncology, Philadelphia, USA
Cohn SL: Section of Hematology/Oncology, Department of Pediatrics, University of Chicago, Chicago
Nakagawara A: Saga Medical Center Koseikan, Saga, Japan
Seeger RC: Division of Hematology/Oncology, Children’s Hospital Los Angeles, Los Angeles, USA
Speleman F: Center for Medical Genetics Ghent, Medical Research Building 1, Ghent, Belgium
Tonini GP: Neuroblastoma Laboratory, Italian Neuroblastoma Foundation, Pediatric Research Institute, Fondazione Città della Speranza, Padua, Italy
Hero B: University of Cologne, Department of Pediatric Oncology and Hematology, University of Cologne, Koeln, Germany
Source impact of the top journals publishing on neuroblastoma
| Source | IF | NP | TC | |||
|---|---|---|---|---|---|---|
| Journal of Neurochemistry | 4.87 | 319 | 10,221 | 53 | 71 | 1.39 |
| Cancer Research | 9.13 | 295 | 19,170 | 80 | 117 | 2.35 |
| Journal of Pediatric Surgery | 2.09 | 278 | 4409 | 33 | 45 | 0.86 |
| Pediatric Blood and Cancer | 2.64 | 261 | 3368 | 27 | 40 | 1.68 |
| Oncogene | 6.85 | 194 | 9223 | 55 | 82 | 1.83 |
| PLOS One | 2.77 | 193 | 3528 | 27 | 43 | 2.07 |
| Neuroscience Letters | 2.15 | 192 | 3568 | 31 | 45 | 0.86 |
| Journal of Clinical Oncology | 26.3 | 180 | 16,426 | 75 | 121 | 2.20 |
| European Journal of Cancer | 7.19 | 178 | 5229 | 40 | 57 | 1.37 |
| International Journal of Cancer | 7.3 | 172 | 5123 | 35 | 74 | 1.22 |
| Cancer Letters | 6.5 | 171 | 4066 | 35 | 48 | 1.12 |
| Clinical Cancer Research | 10.2 | 168 | 7228 | 49 | 70 | 1.96 |
| Biochemical and Biophysical Research Communications | 2.7 | 161 | 3517 | 32 | 48 | 0.78 |
| Cancer | 6.1 | 153 | 6935 | 46 | 76 | 1.15 |
| Journal of Biological Chemistry | 4.1 | 151 | 9197 | 56 | 87 | 1.4 |
| Journal of Pediatric Hematology Oncology | 0.9 | 146 | 1890 | 25 | 38 | 0.96 |
| Brain Research | 2.9 | 137 | 3390 | 30 | 48 | 0.83 |
| Oncotarget | 5.1 | 137 | 1740 | 23 | 30 | 2.3 |
| British Journal of Cancer | 5.9 | 117 | 3684 | 35 | 52 | 0.89 |
Most productive countries contributing to neuroblastoma research
| Region | TP | TC | AAC | |
|---|---|---|---|---|
| USA | 4328 | 141 | 113,525 | 35.45 |
| Japan | 1364 | 76 | 23,268 | 24.66 |
| Italy | 1336 | 78 | 26,134 | 27.85 |
| Germany | 1128 | 85 | 21,597 | 31.19 |
| UK | 910 | 75 | 18,424 | 26.78 |
| China | 829 | 44 | 9144 | 32.61 |
| France | 748 | 70 | 14,846 | 33.24 |
| Sweden | 454 | 56 | 10,149 | 33.16 |
| Spain | 454 | 55 | 7610 | 30.00 |
| Canada | 427 | 52 | 7468 | 27.21 |
| Netherlands | 337 | 54 | 13,184 | 39.12 |
| South Korea | 330 | 34 | 5269 | 15.97 |
TP total production, TC total citations, AAC average article citations
Most cited neuroblastoma papers
| Authors | Article | Journal | Year | Vol | Issue | Page | TC | TC per year |
|---|---|---|---|---|---|---|---|---|
| Broder GM, Pritchard J, Berthold F, Hedborg F | Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. | J Clin Oncol | 1993 | 11 | 8 | 1466–77 | 1450 | 55.7 |
| Kaghad M,Bonnet H, Yang A, Caput D | Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers | Cell | 1997 | 90 | 4 | 809–19 | 1403 | 63.7 |
| Broder GM | Neuroblastoma: Biological insights into a clinical enigma | Nat Rec Cancer | 2003 | 3 | 3 | 203–16 | 1328 | 83.0 |
| Matthay KK, Villablanca JG, Seeger RC, Reynolds | Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid | N Engl J Med | 1999 | 341 | 16 | 1165–73 | 1246 | 62.3 |
| Maris JM, Hogarty MD, Bagatell R, Cohn SL | Neuroblastoma | Lancet | 2010 | 369 | 9579 | 2106–20 | 1153 | 96.1 |
| Maris JM | Recent Advances in Neuroblastoma | N Engl J Med | 2010 | 362 | 23 | 2202–11 | 792 | 88.0 |
| Yu AL, Gilman AL, Ozkaynak MF, Sondel PM | Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma | N Engl J Med | 2010 | 363 | 14 | 1324–34 | 707 | 78.5 |
| Mosse YP, Laudenslager M, Longo L, Maris JM | Identification of ALK as a major familial neuroblastoma predisposition gene | Nature | 2008 | 455 | 7215 | 930–5 | 704 | 64.0 |
| Shimada H, Chatten J, Newton WA, Misugi K | Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas | J Natl Cancer Inst | 1984 | 73 | 2 | 405–16 | 686 | 19.6 |
| Pule M, Savoldo B, Myers GD, Brenner MK | Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma | Nat Med | 2008 | 14 | 11 | 1264–70 | 674 | 61.3 |
first, second, third, and last authors
Fig. 3The keywords co-occurrence network. Minimum number of occurrence of a keyword = 10, minimum links strength = 10. Overall, 1638 keywords met threshold criteria. There are 7 clusters of keywords: red indicates Cluster 1 (n = 449), green indicates Cluster 2 (n = 341), blue indicates Cluster 3 (n = 285), yellow indicates Cluster 4 (n = 246), purple indicates Cluster 5 (n = 214), light-blue indicates Cluster 6 (n = 94), orange indicates Cluster 7 (n = 9)